Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install a large-scale production line with that is scheduled to begin operation in 2027. This comes in response to rapidly growing global demand for nucleic acids, which has been forecast to grow at 14%/year to reach about $9.7 billion in 2030.

“With this, we will become one of Japan’s largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply,” the company stated. “We will strengthen our manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production.”